Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Feb 10;16(4):746.
doi: 10.3390/cancers16040746.

Roles of Androgen Receptor Signaling in Urothelial Carcinoma

Debasish Sundi  1 , Katharine A Collier  2 , Yuanquan Yang  2 , Dayssy Alexandra Diaz  3 , Kamal S Pohar  4 , Eric A Singer  4 , Sanjay Gupta  5 , William E Carson 3rd  6 , Steven K Clinton  7 , Zihai Li  2 , Edward M Messing  8
Affiliations
Review

Roles of Androgen Receptor Signaling in Urothelial Carcinoma

Debasish Sundi et al. Cancers (Basel). .

Abstract

Preclinical and clinical data suggest that androgen receptor signaling strongly contributes to bladder cancer development. The roles of the androgen receptor in bladder carcinogenesis have obvious implications for understanding the strong male sex bias in this disease and for potential therapeutic strategies as well. In this review, we summarize what is known about androgen receptor signaling in urothelial carcinoma as well as in tumor-infiltrating immune cells, reviewing preclinical and clinical data. We also highlight clinical trial efforts in this area.

Keywords: androgen receptor; anti-tumor immunity; bladder cancer.

PubMed Disclaimer

Conflict of interest statement

Y.Y.—advisory board: Exelixis, Eisai. Consulting and honoraria: The Whiteoak Group, AstraZeneca. Research support to institution: Incyte, Amgen, Novartis, Gilead, Recordati Rare Diseases. E.A.S.—advisory board: Merck, Johnson & Johnson, Vyriad. Research support to institution: Medivation/Astellas. Data safety monitoring board: Aura Biosciences. E.M.M.—site investigator for bladder cancer trial sponsored by Protera. Study chair for bladder cancer prevention trial (apalutamide).

Figures

Figure 1
Figure 1
Likely effects of androgen receptor signaling in the bladder cancer microenvironment. Figure created with biorender.com, accessed on 14 December 2023.
Figure 2
Figure 2
AR signaling pathways relevant to anti-tumor immunity. Figure created with biorender.com.
See this image and copyright information in PMC

References

    1. Schafer E.J., Jemal A., Wiese D., Sung H., Kratzer T.B., Islami F., Dahut W.L., Knudsen K.E. Disparities and Trends in Genitourinary Cancer Incidence and Mortality in the USA. Eur. Urol. 2023;84:117–126. doi: 10.1016/j.eururo.2022.11.023. - DOI - PubMed
    1. Antoni S., Ferlay J., Soerjomataram I., Znaor A., Jemal A., Bray F. Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. Eur. Urol. 2017;71:96–108. doi: 10.1016/j.eururo.2016.06.010. - DOI - PubMed
    1. Michaeli J.C., Boch T., Albers S., Michaeli T., Michaeli D.T. Socio-economic burden of disease: Survivorship costs for bladder cancer. J. Cancer Policy. 2022;32:100326. doi: 10.1016/j.jcpo.2022.100326. - DOI - PubMed
    1. Theodorescu D., Li Z., Li X. Sex differences in bladder cancer: Emerging data and call to action. Nat. Rev. Urol. 2022;19:447–449. doi: 10.1038/s41585-022-00591-4. - DOI - PMC - PubMed
    1. Hartge P., Harvey E.B., Linehan W.M., Silverman D.T., Sullivan J.W., Hoover R.N., Fraumeni J.F. Unexplained Excess Risk of Bladder Cancer in Men. JNCI J. Natl. Cancer Inst. 1990;82:1636–1640. doi: 10.1093/jnci/82.20.1636. - DOI - PubMed

LinkOut - more resources